Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Simulations Plus Inc (SLP)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Simulations Plus's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
46.00 +1.00    +2.22%
16:00:00 - Closed. Currency in USD ( Disclaimer )
After Hours
46.00
0.00
0.00%
16:02:15 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 108,363
  • Bid/Ask: 42.90 / 48.38
  • Day's Range: 45.00 - 46.41
Simulations Plus 46.00 +1.00 +2.22%

Simulations Plus Inc Company Profile

 
Get an in-depth profile of Simulations Plus Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryHealthcare Equipment & Supplies
SectorHealthcare
Employees

195

Equity Type

ORD

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, RENAsym, IPFsym, and MITOsym products. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, it offers creative and insightful consulting services to support its quantitative systems pharmacology/quantitative systems toxicology modelling. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.

Contact Information

Address 42505 Tenth Street West
Lancaster, 93534-7059
United States
Phone 661 723 7723
Fax -

Top Executives

Name Age Since Title
David L. Ralph 75 2012 Independent Director
John K. Paglia 54 2014 Independent Director
K. Melissa Hallow - 2021 Member of Scientific Advisory Board
Frank D. Sistare - 2021 Member of Scientific Advisory Board
Ravindra L. Mehta - 2021 Member of Scientific Advisory Board
Lauren Aleksunes - 2021 Member of Scientific Advisory Board
Zheng Dong - 2021 Member of Scientific Advisory Board
Walter S. Woltosz 77 1981 Co-Founder & Chairman
Sharlene Evans 57 2021 Independent Director
Daniel L. Weiner 72 2017 lead Independent Director
Lisa LaVange 68 2019 Independent Director
Paul B. Watkins - 2021 Chairman of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

SLP Comments

Write your thoughts about Simulations Plus Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Pato Stefak
Pato Stefak Apr 03, 2024 12:31PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
stupid garbage, dont but
Nico Al
Nico Al Sep 08, 2020 7:54PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
soon test 72?
Greg Hoff
Greg Hoff Sep 08, 2020 7:54PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Solid long term hold
The Lost
The Lost Jul 07, 2020 1:50AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
61.46
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email